You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Bendamustine for the first-line treatment of chronic lymphocytic leukaemia

  • Technology appraisal guidance
  • Reference number: TA216
  • Published:  23 February 2011
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Leukaemia (lymphocytic) - bendamustine: clarification letters

  • Leukaemia (lymphocytic) - bendamustine: NICE request to the manufacturer for clarification on their submission

  • Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 1

  • Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 2


This page was last updated: 17 December 2010

Back to top